{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T22:54:53Z","timestamp":1790463293207,"version":"4.1.0"},"reference-count":32,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"23","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2019,8,10]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Nivolumab, an anti\u2013programmed death-1 monoclonal antibody, has demonstrated frequent and durable responses in relapsed\/refractory classic Hodgkin lymphoma (cHL). We report results from Cohort D of the CheckMate 205 trial, which assessed nivolumab monotherapy followed by nivolumab plus doxorubicin, vinblastine, and dacarbazine (N-AVD) for newly diagnosed cHL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Patients 18 years of age or older with untreated, advanced-stage (defined as III to IV and IIB with unfavorable risk factors) cHL were eligible for Cohort D of this multicenter, noncomparative, phase II trial. Patients received nivolumab monotherapy for four doses, followed by 12 doses of N-AVD; all doses were every 2 weeks, and nivolumab was administered at 240 mg intravenously. The primary end point was safety. Efficacy end points included objective response rate and modified progression-free survival, defined as time to disease progression\/relapse, death, or next therapy. Chromosome 9p24.1 alterations and programmed death-ligand 1 expression were assessed in Hodgkin Reed-Sternberg cells in evaluable patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>A total of 51 patients were enrolled and treated. At diagnosis, 49% of patients had an International Prognostic Score of 3 or greater. Overall, 59% experienced a grade 3 to 4 treatment-related adverse event. Treatment-related febrile neutropenia was reported in 10% of patients. Endocrine immune-mediated adverse events were all grade 1 to 2 and did not require high-dose corticosteroids; all nonendocrine immune-mediated adverse events resolved (most commonly, rash; 5.9%). At the end of therapy, the objective response rate (95% CI) per independent radiology review committee was 84% (71% to 93%), with 67% (52% to 79%), achieving complete remission (five patients [10%] were nonevaluable and counted as nonresponders). With a minimum follow-up of 9.4 months, 9-month modified progression-free survival was 92%. Patients with higher-level Hodgkin Reed-Sternberg programmed death-ligand 1 expression had more favorable responses to N-AVD ( P = .041).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Nivolumab followed by N-AVD was associated with promising efficacy and safety profiles for newly diagnosed, advanced-stage cHL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.19.00315","type":"journal-article","created":{"date-parts":[[2019,5,21]],"date-time":"2019-05-21T15:59:33Z","timestamp":1558454373000},"page":"1997-2007","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":233,"title":["Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study"],"prefix":"10.1200","volume":"37","author":[{"given":"Radhakrishnan","family":"Ramchandren","sequence":"first","affiliation":[{"name":"University of Tennessee, Knoxville, TN"},{"name":"Barbara Ann Karmanos Cancer Institute, Detroit, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Domingo-Dom\u00e8nech","sequence":"additional","affiliation":[{"name":"Hospital Duran i Reynals, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Rueda","sequence":"additional","affiliation":[{"name":"Costa del Sol Hospital, Marbella, Spain, and Institute of Biomedical Research in M\u00e1laga (IBIMA), M\u00e1laga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Trn\u011bn\u00fd","sequence":"additional","affiliation":[{"name":"Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana A.","family":"Feldman","sequence":"additional","affiliation":[{"name":"John Theurer Cancer Center at Hackensack Meridian Health, Hackensack, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hun Ju","family":"Lee","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Provencio","sequence":"additional","affiliation":[{"name":"Hospital Universitario Puerta de Hierro, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Sillaber","sequence":"additional","affiliation":[{"name":"Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathon B.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerry J.","family":"Savage","sequence":"additional","affiliation":[{"name":"British Columbia Cancer Centre for Lymphoid Cancer, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Willenbacher","sequence":"additional","affiliation":[{"name":"Innsbruck University Hospital, Innsbruck, Austria"},{"name":"OncoTyrol\u2013Center of Personalized Cancer Medicine, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azra H.","family":"Ligon","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Ouyang","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Redd","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J.","family":"Rodig","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, MA"},{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret A.","family":"Shipp","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Sacchi","sequence":"additional","affiliation":[{"name":"Bristol\u2010Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Sumbul","sequence":"additional","affiliation":[{"name":"Bristol\u2010Myers Squibb, Princeton, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.12.086"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.43.4803"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.8820"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1177\/1179554917731072"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1111961"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.6394"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.4482"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.3994"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.0793"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-10-811224"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk029"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-034405"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12222"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.45.4181"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.9774"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510093"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.11.6525"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.1119"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2010.08485.x"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2437_53"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708984"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1989.7.11.1630"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1100340"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.0910"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61469-0"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.7243"},{"key":"B28","doi-asserted-by":"crossref","first-page":"3205","DOI":"10.1200\/JCO.1998.16.9.3205","volume":"16","author":"Willenbacher W","year":"1998","journal-title":"J Clin Oncol"},{"key":"B30","unstructured":"National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology: Hodgkin lymphoma. V3.2018. Fort Washington, PA, National Comprehensive Cancer Network, 2018. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hodgkins.pdf"},{"key":"B32","doi-asserted-by":"crossref","unstructured":"Stephens DM, Li H, Schoder H, et al: Long-term follow-up of SWOG S0816: Response-adapted therapy for stage III\/IV Hodgkin Lymphoma demonstrates limitations of PET-adapted approach. Presented at the American Society of Hematology Annual Meeting, San Diego, December 1-4, 2018","DOI":"10.1182\/blood-2018-99-113034"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718528"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.19.00315","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T06:04:27Z","timestamp":1653804267000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.19.00315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,10]]},"references-count":32,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2019,8,10]]}},"alternative-id":["10.1200\/JCO.19.00315"],"URL":"https:\/\/doi.org\/10.1200\/jco.19.00315","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,10]]},"assertion":[{"value":"2019-04-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}